awmsg logo



vismodegib (Erivedge®)


Reference No. 1037

Publication date:
12/09/2017


Appraisal information

vismodegib (Erivedge®) 150 mg capsule


Company: Roche Products Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 11/01/2017
AWMSG meeting date: 26/04/2017
   
   
Submission Type: Directed
Status: Not recommended
Advice No: 0917
Ministerial ratification: 11/09/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Vismodegib (Erivedge®) is not recommended for use within NHS Wales for the treatment of adult patients with symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy. The case for cost-effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download